Karine Le Malicot

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 8

Top Topics

Prognostic Factors

Top Venues

Current oncology (Toronto, Ont.)

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Emeric Boisteau, Laetitia Dahan, Nicolas Williet, Karine Le Malicot, Jérôme Desramé, Olivier Bouché, Caroline Petorin, David Malka, Christine Rebischung, Thomas Aparicio, Cédric Lecaille, Yves Rinaldi, Anthony Turpin, Anne-Laure Bignon, Jean-Baptiste Bachet, Côme Lepage, Victoire Granger, Jean-Louis Legoux, Gaël Deplanque, Mathieu Baconnier, Thierry Lecomte, Isabelle Bonnet, Jean-François Seitz, Eric François, Astrid Lièvre, null null
Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer. The oncologist (2024)
Jean-Louis Legoux, Roger Faroux, Nicolas Barrière, Karine Le Malicot, David Tougeron, Véronique Lorgis, Véronique Guerin-Meyer, Vincent Bourgeois, David Malka, Thomas Aparicio, Matthieu Baconnier, Valérie Lebrun-Ly, Joëlle Egreteau, Faïza Khemissa Akouz, Magali Terme, Côme Lepage, Valérie Boige
First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA). Cancers 16 (8) (2024)
Jean-Louis Legoux, Roger Faroux, Nicolas Barrière, Karine Le Malicot, David Tougeron, Véronique Lorgis, Véronique Guerin-Meyer, Vincent Bourgeois, David Malka, Thomas Aparicio, Matthieu Baconnier, Valérie Lebrun-Ly, Joëlle Egreteau, Faïza Khemissa Akouz, Magali Terme, Côme Lepage, Valérie Boige
First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA). Cancers 16 (8) (2024)
Elodie Martin, Karine Le Malicot, Catherine Guerin-Charbonnel, François Bocquet, Olivier Bouche, Anthony Turpin, Thomas Aparicio, Jean-Louis Legoux, Laetitia Dahan, Julien Taieb, Côme Lepage, Louis-Marie Dourthe, Caroline Pétorin, Vincent Bourgeois, Jean-Luc Raoul, Valérie Seegers
How to Balance Prognostic Factors in Controlled Phase II Trials: Stratified Permuted Block Randomization or Minimization? An Analysis of Clinical Trials in Digestive Oncology. Current oncology (Toronto, Ont.) 31 (6) (2024)
Elodie Martin, Karine Le Malicot, Catherine Guerin-Charbonnel, François Bocquet, Olivier Bouche, Anthony Turpin, Thomas Aparicio, Jean-Louis Legoux, Laetitia Dahan, Julien Taieb, Côme Lepage, Louis-Marie Dourthe, Caroline Pétorin, Vincent Bourgeois, Jean-Luc Raoul, Valérie Seegers
How to Balance Prognostic Factors in Controlled Phase II Trials: Stratified Permuted Block Randomization or Minimization? An Analysis of Clinical Trials in Digestive Oncology. Current oncology (Toronto, Ont.) 31 (6) (2024)
Clémence Canton, Olayidé Boussari, Mathieu Boulin, Karine Le Malicot, Gilles Manceau, Laetitia Dahan, Anthony Lopez, Come Lepage, Jean-Baptiste Bachet
Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma. The oncologist 27 (7) (2022)
Laetitia Marisa, Yuna Blum, Gilles Manceau, Mira Ayadi, Camilla Pilati, Karine Le Malicot, Côme Lepage, Ramón Salazar, Daniela Aust, Alex Duval, Hélène Blons, Valérie Taly, David Gentien, Audrey Rapinat, Janick Selves, Sophie Mouillet-Richard, Valérie Boige, Jean François Emile, Aurélien de Reyniès, Pierre Laurent-Puig
Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (17) (2021)
Laetitia Dahan, Nicolas Williet, Karine Le Malicot, Jean Marc Phelip, Jérôme Desrame, Olivier Bouché, Caroline Petorin, David Malka, Christine Rebischung, Thomas Aparicio, Cédric Lecaille, Yves Rinaldi, Anthony Turpin, Anne-Laure Bignon, Jean-Baptiste Bachet, Jean-François Seitz, Côme Lepage, Eric François, null null
Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (29) (2021)